ProKidney Corp. reported its financial results for the first quarter of 2026, revealing a slight decrease in revenue and an increase in operating expenses compared to the same period in 2025. The company generated revenue of $226,000, down from $230,000 in the prior year. Operating expenses rose to $45.2 million, up from $41.6 million, primarily driven by increased research and development costs associated with the ongoing Phase 3 clinical trial of its lead product candidate, rilparencel. The net loss for the quarter was $42.6 million, compared to a net loss of $37.4 million in the same quarter last year.
The increase in research and development expenses, which totaled $33.8 million for the quarter, was largely attributed to heightened clinical study costs and manufacturing materials for the rilparencel trial. This was partially offset by a decrease in costs related to completed or terminated clinical studies. General and administrative expenses decreased to $11.3 million from $14.4 million, reflecting lower equity-based compensation and professional fees associated with the company's restructuring efforts.
ProKidney's total assets as of March 31, 2026, were reported at $292.8 million, a decrease from $335.6 million at the end of 2025. The decline in total assets was primarily due to a reduction in cash and marketable securities, which fell to $224.9 million from $270 million. The company’s cash and cash equivalents stood at $101.9 million, down from $108.5 million at the end of the previous fiscal year. The company also reported a total stockholders' deficit of $1.02 billion, compared to $1.01 billion at the end of 2025.
In terms of operational developments, ProKidney is focused on advancing its clinical trials for rilparencel, which aims to preserve kidney function in patients with advanced chronic kidney disease and type 2 diabetes. The company is currently conducting a Phase 3 study with a targeted enrollment of approximately 470 patients across clinical centers in the United States, Mexico, and Taiwan. The anticipated topline data readout for the surrogate endpoint is expected in the second quarter of 2027.
Looking ahead, ProKidney expects to continue incurring significant expenses as it progresses through its clinical trials and seeks regulatory approvals for rilparencel. The company has indicated that it will need substantial additional funding to support its operations and growth strategy, as it does not anticipate generating revenue from product sales in the near future. ProKidney's management remains focused on securing the necessary capital to sustain its research and development efforts while navigating the uncertainties inherent in the biotechnology sector.
About PROKIDNEY CORP.
ProKidney Corp. is a clinical-stage biotechnology company developing autologous cell therapies to treat chronic kidney disease (CKD). Its lead product, rilparencel, uses patient-derived kidney cells to preserve kidney function and delay progression to end-stage renal disease. The company focuses on regenerative medicine, clinical trials, and manufacturing personalized therapies, targeting markets with high unmet needs in CKD management and aiming for regulatory approval and commercialization.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.